Could an SGLT2 inhibitor change the inflammatory biology around the coronary artery?
A newly registered randomised trial is asking a more interesting question about dapagliflozin than whether it lowers HbA1c.
The study will give dapagliflozin 10 mg daily for 18 months to people with type 2 diabetes and coronary atherosclerosis, then examine whether it slows coronary plaque progression.
The proposed mechanism includes a target we do not talk about enough:
perivascular adipose tissue, or PVAT.
I trained in medicine in the mid to late 1990s and early 2000s. I do not remember PVAT being part of the clinical mental model in any serious way.
We were taught vessels, plaques, blood pressure, cholesterol, glucose and risk factors.
The tissue environment around the artery did not really feature.
But PVAT is not passive padding.
It is adipose tissue wrapped directly around blood vessels. In health, it helps regulate vascular tone and local signalling. In obesity, hypertension and diabetes, it can become inflammatory, altering adipokine release, oxidative stress, endothelial function and vascular relaxation.
The artery is not just exposed to abnormal glucose and circulating lipids.
It is sitting inside an abnormal local signalling environment.
SGLT2 inhibitors already have a serious cardiovascular and renal evidence base across diabetes, chronic kidney disease and heart failure.
But the next question is more bio-environmental
How much of their benefit comes from changing the tissue environment in which vascular disease develops?
If dapagliflozin can favourably influence PVAT biology, vascular inflammation and coronary plaque trajectory, then we are not just treating a blood result. We may be modifying part of the vascular ageing niche.
That is the translational inference.
And it is an inference.
This trial has not yet reported. It is being conducted in people with type 2 diabetes and coronary atherosclerosis. It does not prove that SGLT2 inhibitors should be used as vascular anti-ageing drugs in metabolically healthy people.
But it raises a better clinical question than another sterile argument about whether an HbA1c of 42 or 44 mmol/mol is “normal”.
Are we treating the biomarker, or the tissue biology driving the trajectory?
The right patient is not “anyone who wants to live longer”.
It may be someone with central adiposity, insulin resistance, vascular risk, early renal vulnerability or established cardiometabolic disease, where an SGLT2 inhibitor is already clinically defensible and may also be acting on deeper vascular biology.
Scout-led medicine asks the translational question early.
Doctor-governed medicine keeps the phenotype, safety, consent and monitoring honest.
SGLT2 inhibitors may become one of the more important longevity-adjacent drug classes because they sit at the intersection of metabolism, vascular inflammation, renal protection and tissue-level ageing biology.
References
ClinicalTrials.gov — NCT07614230
SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes.
Sowa H et al.
Perivascular adipose tissue and vascular inflammation: from biological insights to clinical implications.
Frontiers in Physiology, 2026.
Ueda K.
Perivascular adipose tissue in cardiovascular disease: from mechanisms to therapeutic targets.
Circulation Journal, e-published 2025 / journal issue 2026.
Liu X et al.
Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index.
Cardiovascular Diabetology, 2025.
Alshnbari AS et al.
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies.
Diabetes Therapy, 2020.

